395 related articles for article (PubMed ID: 30651070)
41. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
[TBL] [Abstract][Full Text] [Related]
42. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation.
Gärtner BC; Jung W; Welsch C; Fischinger J; Schubert J; Zeuzem S; Mueller-Lantzsch N; Wend UC; Gerlich WH
J Clin Virol; 2007 Feb; 38(2):146-8. PubMed ID: 17182277
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation.
Hammond SP; Borchelt AM; Ukomadu C; Ho VT; Baden LR; Marty FM
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1049-59. PubMed ID: 19660717
[TBL] [Abstract][Full Text] [Related]
44. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
46. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
47. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy.
Lee JY; Lim SH; Lee MY; Kim H; Sinn DH; Gwak GY; Choi MS; Lee JH; Jung CW; Jang JH; Kim WS; Kim SJ; Kim K
Liver Int; 2015 Nov; 35(11):2363-9. PubMed ID: 25832927
[TBL] [Abstract][Full Text] [Related]
48. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
49. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
Sayar S; Kürbüz K; Kahraman R; Öztürk O; Çalışkan Z; Doğanay HL; Özdil K
Turk J Gastroenterol; 2020 Jul; 31(7):522-528. PubMed ID: 32897226
[TBL] [Abstract][Full Text] [Related]
50. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
51. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation.
Goyama S; Kanda Y; Nannya Y; Kawazu M; Takeshita M; Niino M; Komeno Y; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Shiratori Y; Hirai H
Leuk Lymphoma; 2002 Nov; 43(11):2159-63. PubMed ID: 12533042
[TBL] [Abstract][Full Text] [Related]
52. Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection.
Kong D; Wu D; Wang T; Li T; Xu S; Chen F; Jin X; Lou G
Int J Infect Dis; 2013 Jul; 17(7):e535-8. PubMed ID: 23474175
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
54. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience.
Faraci M; Cappelli B; Lanino E; Morreale G; Fioredda F; Giudice CL; Giacchino R
Pediatr Transplant; 2009 Nov; 13(7):923-6. PubMed ID: 19032422
[TBL] [Abstract][Full Text] [Related]
55. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
56. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
57. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
Yaşar DG; Suyanı E; Özenirler S; Sucak GT
Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
[TBL] [Abstract][Full Text] [Related]
58. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.
Ceneli O; Ozkurt ZN; Acar K; Rota S; Aki SZ; Yeğin ZA; Yağci M; Ozenirler S; Sucak GT
World J Gastroenterol; 2010 Apr; 16(14):1765-71. PubMed ID: 20380010
[TBL] [Abstract][Full Text] [Related]
60. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
Serper M; Forde KA; Kaplan DE
J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
